Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN.

Krege JH, Rizzoli PB, Liffick E, Doty EG, Dowsett SA, Wang J, Buchanan AS.

Cephalalgia. 2019 Jun 5:333102419855080. doi: 10.1177/0333102419855080. [Epub ahead of print]

PMID:
31166697
2.

Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials.

Tepper SJ, Krege JH, Lombard L, Asafu-Adjei JK, Dowsett SA, Raskin J, Buchanan AS, Friedman DI.

Headache. 2019 Jun 1. doi: 10.1111/head.13544. [Epub ahead of print]

PMID:
31152441
3.

Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies.

Silverman S, Langdahl BL, Fujiwara S, Saag K, Napoli N, Soen S, Enomoto H, Melby TE, Disch DP, Marin F, Krege JH.

Calcif Tissue Int. 2019 Feb;104(2):193-200. doi: 10.1007/s00223-018-0485-2. Epub 2018 Oct 20.

PMID:
30343436
4.

Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis.

Díez-Pérez A, Marin F, Eriksen EF, Kendler DL, Krege JH, Delgado-Rodríguez M.

Bone. 2019 Mar;120:1-8. doi: 10.1016/j.bone.2018.09.020. Epub 2018 Sep 27.

5.

Teriparatide Treatment Increases Mineral Content and Volume in Cortical and Trabecular Bone of Iliac Crest: A Comparison of Infrared Imaging With X-Ray-Based Bone Assessment Techniques.

Paschalis EP, Krege JH, Gamsjaeger S, Eriksen EF, Burr DB, Disch DP, Stepan JJ, Fahrleitner-Pammer A, Klaushofer K, Marin F, Pavo I.

J Bone Miner Res. 2018 Dec;33(12):2230-2235. doi: 10.1002/jbmr.3565. Epub 2018 Sep 14.

PMID:
30102789
6.

Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies.

Langdahl BL, Silverman S, Fujiwara S, Saag K, Napoli N, Soen S, Enomoto H, Melby TE, Disch DP, Marin F, Krege JH.

Bone. 2018 Nov;116:58-66. doi: 10.1016/j.bone.2018.07.013. Epub 2018 Jul 18.

PMID:
30021126
7.

Remodeling- and Modeling-Based Bone Formation With Teriparatide Versus Denosumab: A Longitudinal Analysis From Baseline to 3 Months in the AVA Study.

Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Melby TE, Ruff VA.

J Bone Miner Res. 2018 Feb;33(2):298-306. doi: 10.1002/jbmr.3309. Epub 2017 Nov 15.

8.

Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS).

Soen S, Fujiwara S, Takayanagi R, Kajimoto K, Tsujimoto M, Kimura S, Sato M, Krege JH, Enomoto H.

Curr Med Res Opin. 2017 Nov;33(11):2049-2056. doi: 10.1080/03007995.2017.1354826. Epub 2017 Aug 4.

PMID:
28699789
9.

Spine fracture prevalence in a nationally representative sample of US women and men aged ≥40 years: results from the National Health and Nutrition Examination Survey (NHANES) 2013-2014.

Cosman F, Krege JH, Looker AC, Schousboe JT, Fan B, Sarafrazi Isfahani N, Shepherd JA, Krohn KD, Steiger P, Wilson KE, Genant HK.

Osteoporos Int. 2017 Jun;28(6):1857-1866. doi: 10.1007/s00198-017-3948-9. Epub 2017 Feb 7.

PMID:
28175980
10.

Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.

Burge RT, Disch DP, Gelwicks S, Zhang X, Krege JH.

Osteoporos Int. 2017 Mar;28(3):799-809. doi: 10.1007/s00198-016-3888-9. Epub 2016 Dec 27.

11.

Teriparatide in patients with osteoporosis and type 2 diabetes.

Schwartz AV, Pavo I, Alam J, Disch DP, Schuster D, Harris JM, Krege JH.

Bone. 2016 Oct;91:152-8. doi: 10.1016/j.bone.2016.06.017. Epub 2016 Jul 1.

PMID:
27374026
12.

Improvement of cancellous bone microstructure in patients on teriparatide following alendronate pretreatment.

Fahrleitner-Pammer A, Burr D, Dobnig H, Stepan JJ, Petto H, Li J, Krege JH, Pavo I.

Bone. 2016 Aug;89:16-24. doi: 10.1016/j.bone.2016.05.004. Epub 2016 May 13.

13.

Reference point indentation is insufficient for detecting alterations in traditional mechanical properties of bone under common experimental conditions.

Krege JB, Aref MW, McNerny E, Wallace JM, Organ JM, Allen MR.

Bone. 2016 Jun;87:97-101. doi: 10.1016/j.bone.2016.04.002. Epub 2016 Apr 9.

14.

Teriparatide for osteoporosis: importance of the full course.

Lindsay R, Krege JH, Marin F, Jin L, Stepan JJ.

Osteoporos Int. 2016 Aug;27(8):2395-410. doi: 10.1007/s00198-016-3534-6. Epub 2016 Feb 22. Review.

15.

Differential Effects of Teriparatide and Denosumab on Intact PTH and Bone Formation Indices: AVA Osteoporosis Study.

Dempster DW, Zhou H, Recker RR, Brown JP, Recknor CP, Lewiecki EM, Miller PD, Rao SD, Kendler DL, Lindsay R, Krege JH, Alam J, Taylor KA, Janos B, Ruff VA.

J Clin Endocrinol Metab. 2016 Apr;101(4):1353-63. doi: 10.1210/jc.2015-4181. Epub 2016 Feb 9.

16.

Patients with prior vertebral or hip fractures treated with teriparatide in the Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) observational study.

Beall DP, Feldman RG, Gordon ML, Gruber BL, Lane JM, Valenzuela G, Yim D, Alam J, Krege JH, Krohn K.

Osteoporos Int. 2016 Mar;27(3):1191-1198. doi: 10.1007/s00198-015-3353-1. Epub 2015 Nov 10.

PMID:
26556737
17.

Japan Fracture Observational Study (JFOS): patient characteristics and interim data on the use of daily teriparatide in Japanese patients with osteoporosis.

Soen S, Fujiwara S, Takayanagi R, Sato M, Tsujimoto M, Yamamoto T, Enomoto H, Krege JH.

Curr Med Res Opin. 2015;31(9):1771-9. doi: 10.1185/03007995.2015.1074063. Epub 2015 Sep 4. Erratum in: Curr Med Res Opin. 2016 Oct;32(10):1767-1768.

PMID:
26189932
18.

Teriparatide fracture effectiveness in the real world.

Krege JH, Burge RT, Marin F.

Osteoporos Int. 2015 Aug;26(8):2217-8. doi: 10.1007/s00198-015-3140-z. Epub 2015 Apr 24. No abstract available.

PMID:
25906242
19.

Relationship Between Vertebral Fracture Burden, Height Loss, and Pulmonary Function in Postmenopausal Women With Osteoporosis.

Krege JH, Kendler D, Krohn K, Genant H, Alam J, Berclaz PY, Coffey B, Loghin C.

J Clin Densitom. 2015 Oct-Dec;18(4):506-11. doi: 10.1016/j.jocd.2015.02.004. Epub 2015 Mar 29.

20.

A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density.

Recker RR, Benson CT, Matsumoto T, Bolognese MA, Robins DA, Alam J, Chiang AY, Hu L, Krege JH, Sowa H, Mitlak BH, Myers SL.

J Bone Miner Res. 2015 Feb;30(2):216-24. doi: 10.1002/jbmr.2351.

21.

Literature review: The effects of teriparatide therapy at the hip in patients with osteoporosis.

Eriksen EF, Keaveny TM, Gallagher ER, Krege JH.

Bone. 2014 Oct;67:246-56. doi: 10.1016/j.bone.2014.07.014. Epub 2014 Jul 15. Review.

22.

PINP as a biological response marker during teriparatide treatment for osteoporosis.

Krege JH, Lane NE, Harris JM, Miller PD.

Osteoporos Int. 2014 Sep;25(9):2159-71. doi: 10.1007/s00198-014-2646-0. Epub 2014 Mar 6. Review.

23.

Association between teriparatide adherence and healthcare utilization and costs among hip fracture patients in the United States.

Zhao Y, Johnston SS, Smith DM, McMorrow D, Krege J, Krohn K.

Bone. 2014 Mar;60:221-6. doi: 10.1016/j.bone.2013.12.016. Epub 2013 Dec 18.

PMID:
24361596
24.

Fracture risk prediction: importance of age, BMD and spine fracture status.

Krege JH, Wan X, Lentle BC, Berger C, Langsetmo L, Adachi JD, Prior JC, Tenenhouse A, Brown JP, Kreiger N, Olszynski WP, Josse RG, Goltzman D; CaMos Research Group.

Bonekey Rep. 2013 Sep 4;2:404. doi: 10.1038/bonekey.2013.138. eCollection 2013.

25.

Association between teriparatide adherence and healthcare utilization and costs in real-world US kyphoplasty/vertebroplasty patients.

Zhao Y, Johnston SS, Smith DM, McMorrow D, Krohn K, Krege J.

Osteoporos Int. 2013 Sep;24(9):2525-33. doi: 10.1007/s00198-013-2324-7. Epub 2013 Mar 26.

PMID:
23529293
26.

Fractures in women treated with raloxifene or alendronate: a retrospective database analysis.

Foster SA, Shi N, Curkendall S, Stock J, Chu BC, Burge R, Diakun DR, Krege JH.

BMC Womens Health. 2013 Mar 23;13:15. doi: 10.1186/1472-6874-13-15.

27.

Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.

Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, Krege JH.

J Bone Miner Res. 2013 Jun;28(6):1328-36. doi: 10.1002/jbmr.1853.

28.

National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges.

Bauer D, Krege J, Lane N, Leary E, Libanati C, Miller P, Myers G, Silverman S, Vesper HW, Lee D, Payette M, Randall S.

Osteoporos Int. 2012 Oct;23(10):2425-33. doi: 10.1007/s00198-012-2049-z. Epub 2012 Jul 14.

29.

Changes in vitamin D metabolites during teriparatide treatment.

Cosman F, Dawson-Hughes B, Wan X, Krege JH.

Bone. 2012 Jun;50(6):1368-71. doi: 10.1016/j.bone.2012.02.635. Epub 2012 Mar 9.

PMID:
22426307
30.

The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.

Hadji P, Zanchetta JR, Russo L, Recknor CP, Saag KG, McKiernan FE, Silverman SL, Alam J, Burge RT, Krege JH, Lakshmanan MC, Masica DN, Mitlak BH, Stock JL.

Osteoporos Int. 2012 Aug;23(8):2141-50. doi: 10.1007/s00198-011-1856-y. Epub 2011 Dec 13.

PMID:
22159672
31.

Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis.

Krege JH, Wan X.

Bone. 2012 Jan;50(1):161-4. doi: 10.1016/j.bone.2011.10.018. Epub 2011 Oct 22.

PMID:
22036910
32.

Long-term raloxifene for postmenopausal osteoporosis.

Recker RR, Mitlak BH, Ni X, Krege JH.

Curr Med Res Opin. 2011 Sep;27(9):1755-61. doi: 10.1185/03007995.2011.606312. Epub 2011 Jul 25. Review.

PMID:
21787127
33.

PINP as an aid for monitoring patients treated with teriparatide.

Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH.

Bone. 2011 Apr 1;48(4):798-803. doi: 10.1016/j.bone.2010.12.006. Epub 2010 Dec 17.

PMID:
21168536
34.

Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide.

Eastell R, Rogers A, Ni X, Krege JH.

Osteoporos Int. 2011 Jun;22(6):1927-34. doi: 10.1007/s00198-010-1380-5. Epub 2010 Sep 14.

PMID:
20838771
35.

Genetically determined angiotensin converting enzyme level and myocardial tolerance to ischemia.

Messadi E, Vincent MP, Griol-Charhbili V, Mandet C, Colucci J, Krege JH, Bruneval P, Bouby N, Smithies O, Alhenc-Gelas F, Richer C.

FASEB J. 2010 Dec;24(12):4691-700. doi: 10.1096/fj.10-165902. Epub 2010 Jul 28.

36.

Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.

Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH.

Bone. 2010 Apr;46(4):935-9. doi: 10.1016/j.bone.2009.12.032. Epub 2010 Jan 6.

PMID:
20060081
37.

Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.

Eastell R, Chen P, Saag KG, Burshell AL, Wong M, Warner MR, Krege JH.

Bone. 2010 Apr;46(4):929-34. doi: 10.1016/j.bone.2009.12.021. Epub 2010 Jan 6.

PMID:
20060078
38.

First fractures among postmenopausal women with osteoporosis.

Sontag A, Krege JH.

J Bone Miner Metab. 2010 Jul;28(4):485-8. doi: 10.1007/s00774-009-0144-9. Epub 2010 Jan 7.

PMID:
20052602
39.

Benefits and risks of raloxifene by vertebral fracture status.

Sontag A, Wan X, Krege JH.

Curr Med Res Opin. 2010 Jan;26(1):71-6. doi: 10.1185/03007990903427082.

PMID:
19908937
40.

Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.

Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, Krege JH, Krohn K, Warner MR.

Arthritis Rheum. 2009 Nov;60(11):3346-55. doi: 10.1002/art.24879.

41.

Antigen-dependent rescue of nose-associated lymphoid tissue (NALT) development independent of LTbetaR and CXCR5 signaling.

Krege J, Seth S, Hardtke S, Davalos-Misslitz AC, Förster R.

Eur J Immunol. 2009 Oct;39(10):2765-78. doi: 10.1002/eji.200939422.

42.

Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, Krege JH.

J Clin Endocrinol Metab. 2009 Oct;94(10):3772-80. doi: 10.1210/jc.2008-2719. Epub 2009 Jul 7.

PMID:
19584192
43.

Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass.

Bolognese M, Krege JH, Utian WH, Feldman R, Broy S, Meats DL, Alam J, Lakshmanan M, Omizo M.

J Clin Endocrinol Metab. 2009 Jul;94(7):2284-9. doi: 10.1210/jc.2008-2143. Epub 2009 Apr 7.

PMID:
19351734
44.

Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment.

Prevrhal S, Krege JH, Chen P, Genant H, Black DM.

Curr Med Res Opin. 2009 Apr;25(4):921-8. doi: 10.1185/03007990902790993 .

PMID:
19250060
45.

Vertebral fracture status and the World Health Organization risk factors for predicting osteoporotic fracture risk.

Chen P, Krege JH, Adachi JD, Prior JC, Tenenhouse A, Brown JP, Papadimitropoulos E, Kreiger N, Olszynski WP, Josse RG, Goltzman D; CaMOS Research Group.

J Bone Miner Res. 2009 Mar;24(3):495-502. doi: 10.1359/jbmr.081103.

46.

Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis.

Lindsay R, Miller P, Pohl G, Glass EV, Chen P, Krege JH.

Osteoporos Int. 2009 Jun;20(6):943-8. doi: 10.1007/s00198-008-0766-0. Epub 2008 Oct 16.

PMID:
18923884
47.

Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.

Wermers RA, Recknor CP, Cosman F, Xie L, Glass EV, Krege JH.

Osteoporos Int. 2008 Jul;19(7):1055-65. doi: 10.1007/s00198-007-0557-z. Epub 2008 Feb 19.

PMID:
18283386
48.

Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency.

Dawson-Hughes B, Chen P, Krege JH.

J Clin Endocrinol Metab. 2007 Dec;92(12):4630-6. Epub 2007 Oct 2.

PMID:
17911178
49.

Occurrence of hypercalciuria in patients with osteoporosis treated with teriparatide.

Miller PD, Bilezikian JP, Diaz-Curiel M, Chen P, Marin F, Krege JH, Wong M, Marcus R.

J Clin Endocrinol Metab. 2007 Sep;92(9):3535-41. Epub 2007 Jul 3.

PMID:
17609307
50.

Enhanced prediction of fracture risk combining vertebral fracture status and BMD.

Siris ES, Genant HK, Laster AJ, Chen P, Misurski DA, Krege JH.

Osteoporos Int. 2007 Jun;18(6):761-70. Epub 2007 Jan 24.

PMID:
17245546

Supplemental Content

Support Center